{"id":"NCT05460325","sponsor":"Takeda","briefTitle":"A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)","officialTitle":"A Multi-center, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Lanadelumab (SHP643) in Chinese Subjects With Hereditary Angioedema","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-06-22","primaryCompletion":"2023-11-28","completion":"2023-11-28","firstPosted":"2022-07-15","resultsPosted":"2024-12-13","lastUpdate":"2024-12-13"},"enrollment":20,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hereditary Angioedema (HAE)"],"interventions":[{"type":"DRUG","name":"Lanadelumab","otherNames":["SHP643","TAKHZYRO","TAK-743","DX-2930","Lanadelumab Injection"]}],"arms":[{"label":"Lanadelumab 300 mg","type":"EXPERIMENTAL"}],"summary":"The main aim of this study is to evaluate the safety of lanadelumab in Chinese participants with HAE.\n\nParticipants will be treated with lanadelumab for 26 weeks.","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)","timeFrame":"From first dose of study drug up to end of study (up to Day 210)","effectByArm":[{"arm":"Lanadelumab 300 mg","deltaMin":15,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":4,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/43d15f0fe5c54538"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":20},"commonTop":["COVID-19","Injection site pain","Injection site swelling","Nausea","Abdominal pain upper"]}}